[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360590-105":59,"doc-detail-360590-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pooled-analysis-of-2-clinical-trials-of-first-line-chemoimmunotherapy-for-metastatic-microsatellite-stable-colorectal-cancer-research-article","Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer - Research article","","First-line treatment for metastatic microsatellite stable (MSS) colorectal cancer remains challenging because MSS status is intrinsically resistant to PD-1/PD-L1 checkpoint inhibitor monotherapy. A pooled analysis used individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors. Overall survival, progression-free survival, and response were compared between chemotherapy alone and chemoimmunotherapy, with associations explored using transcriptomic and immunoscore data. Chemoimmunotherapy improved overall survival and complete response, with CD8+ T-cell infiltration linked to better outcomes in the combination group.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pooled-analysis-of-2-clinical-trials-of-first-line-chemoimmunotherapy-for-metastatic-microsatellite-stable-colorectal-cancer-research-article/360590/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pooled-analysis-of-2-clinical-trials-of-first-line-chemoimmunotherapy-for-metastatic-microsatellite-stable-colorectal-cancer-research-article/360590.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main clinical problem addressed in this pooled analysis?","Question",{"text":112,"@type":113},"Metastatic microsatellite stable (MSS) colorectal cancer is resistant to PD-1/PD-L1 checkpoint inhibitor monotherapy, limiting effective first-line treatment options.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the two phase II trials combined in the analysis?",{"text":117,"@type":113},"Individual patient data were pooled from two phase II trials: MEDITREME (single-arm durvalumab plus tremelimumab with oxaliplatin-based chemotherapy) and METIMMOX (oxaliplatin-based chemotherapy versus an alternating oxaliplatin-based regimen with nivolumab).",{"name":119,"@type":110,"acceptedAnswer":120},"Which outcomes showed benefit with chemoimmunotherapy?",{"text":121,"@type":113},"Overall survival was significantly improved and complete response rates were higher with chemoimmunotherapy versus chemotherapy alone, while progression-free survival did not show significant differences.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360590,1790190945,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ONCOIMMUNOLOGY  \n2026, VOL. 15, NO. 1, 2671491  \n[https://doi.org/10.1080/2162402X.2026.2671491](https://doi.org/10.1080/2162402X.2026.2671491)  \nRESEARCH ARTICLE     \nPooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies  \nCaroline Truntzera, 1 , Marion Thibaudina, 1, Paula Anna Bousquetb , Morgane Peroza, Valentin Derangèrea, Alis Iliea, David Rageota, Kjersti Flatmarkb,c,d, Anne Hansen Reeb,e , Sebastian Meltzerb, 1  and François Ghiringhellia,f, 1   \naUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France; bAkershus University Hospital, Lorenskog, Norway; cDepartment of Gastroenterological Surgery, Oslo University Hospital, Oslo, Norway; dDepartment of Tumor Biology, Oslo University Hospital, Oslo, Norway; eInstitute of Clinical Medicine, University of Oslo, Oslo, Norway; fDepartment of Medical Oncology, Centre Régional De Lutte Contre Le Cancer Georges-François Leclerc, Dijon, France  \nABSTRACT  \nBackground: Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1 . However, emerging evidence suggests that chemotherapies may overcome this resistance when combined with immunotherapy.  \nMethods: We conducted a pooled analysis of individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors as first-line treatment for MSS metastatic colorectal cancer. The MEDITREME trial is a single-arm study assessing durvalumab and tremelimumab with oxaliplatin-based chemotherapy, while the METIMMOX trial is a randomized study comparing standard oxaliplatin-based chemotherapy with an alternating regimen of oxaliplatin-based chemotherapy and nivolumab. We compared overall survival (OS), progression-free survival (PFS), and response rates between patients treated with chemotherapy alone versus chemoimmunotherapy, and evaluated the association between these outcomesand transcriptomic and immunoscore data.  \nResults: A total of 130 patients were included: 38 who received chemotherapy alone and 92 chemoimmunotherapy. The median OS was significantly improved in the chemoimmunotherapy group compared with chemotherapy alone (not reached vs. 15.3 months; HR = 0.58; 95% CI, 0.36–0.96; p = 0.03) . The complete response rates were higher with chemoimmunotherapy (14% vs. 5%) . No significant differences were observed in PFS. High baseline CD8+ T-cell infiltration was associated with improved outcomes in patients receiving chemoimmunotherapy but not in those treated with chemotherapy alone.  \nConclusions: This pooled analysis provides compelling evidence supporting the clinical benefit of first-line chemoimmunotherapy in a subset of patients with MSS mCRC. Baseline CD8+ T-cell infiltration may serve as a predictive biomarker for identifying patients most likely to benefit from this treatment approach.  \nARTICLE HISTORY  \nReceived 10 February 2026 Revised 27 April 2026 Accepted 3 May 2026  \nKEYWORDS  \nColorectal cancer;  \nmicrosatellite stable; immunotherapy; chemotherapy; CD8; biomarkers  \nBackground  \nColorectal cancer (CRC) is a heterogeneous disease that can be broadly divided into two major clinical groups: tumors with deficient mismatch repair (dMMR) or microsatellite instable (MSI), and tumors with proficient mismatch repair (pMMR) or microsatellite stable (MSS) status. Both MSS and MSI tumors are infiltrated by immune cells, 1 and high levels of CD3+ or CD8+ T-cell infiltration are associated with improved survival in patients with either localized or metastatic disease across both tumor types.2 Despite  \nCONTACT François Ghiringhelli  [fghiringhelli@cgfl.fr](fghiringhelli@cgfl.fr)  Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer 1Biology Transfer Platform, I","cbCaimgYUdVfUxYi","https://ap.wps.com/l/cbCaimgYUdVfUxYi","pdf",1445999,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Article Information","[{\"question\":\"What is the main clinical problem addressed in this pooled analysis?\",\"answer\":\"Metastatic microsatellite stable (MSS) colorectal cancer is resistant to PD-1/PD-L1 checkpoint inhibitor monotherapy, limiting effective first-line treatment options.\"},{\"question\":\"How were the two phase II trials combined in the analysis?\",\"answer\":\"Individual patient data were pooled from two phase II trials: MEDITREME (single-arm durvalumab plus tremelimumab with oxaliplatin-based chemotherapy) and METIMMOX (oxaliplatin-based chemotherapy versus an alternating oxaliplatin-based regimen with nivolumab).\"},{\"question\":\"Which outcomes showed benefit with chemoimmunotherapy?\",\"answer\":\"Overall survival was significantly improved and complete response rates were higher with chemoimmunotherapy versus chemotherapy alone, while progression-free survival did not show significant differences.\"}]","Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer - Research article | PDF",1790140634,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6d1ba4d1a9902b4336540ef189c5465.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc771980411325060ee1395fe73edf8a.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92e935fcc08ad3efc643c90da419a187.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4247cca05683f0983a4c726d528b6e36.webp",980,1306]